You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune checkpoint inhibitor (nivolumab)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)

Enrolling by invitation
  • Malignant Ascites
  • Taichung, Please Select, Taiwan
    China Medical University Hospital
Feb 16, 2023

Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

Active, not recruiting
  • Melanoma
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
  • Toulouse, France
    Institut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022

Adverse Events-related Healthcare Resource Utilization and Costs

Completed
  • Melanoma
  • East Hanover, New Jersey
    Novartis Pharmaceuticals
Jan 27, 2023

Oligometastatic Disease Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

Not yet recruiting
  • Oligometastatic Disease
  • (no location specified)
May 5, 2023

Oligoprogressive Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

Not yet recruiting
  • Oligoprogressive
  • (no location specified)
May 5, 2023

Metastatic Melanoma, Skin Cancer Trial in Boston (Ipilimumab, Nivolumab, Cryoablation)

Not yet recruiting
  • Metastatic Melanoma
  • Skin Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Mar 9, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Neck Cancer Metastatic Trial in Baltimore (Nivolumab 480mg and

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Nivolumab 480mg and surgical resection
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Feb 25, 2022

Sarcoma, HER-2 Protein Overexpression Trial in Houston (cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product)

Recruiting
  • Sarcoma
  • HER-2 Protein Overexpression
  • cells
  • +3 more
  • Houston, Texas
    Texas Children's Hospital
Dec 8, 2021

Glioma, Malignant Trial in United States (biological, drug, radiation, other)

Active, not recruiting
  • Glioma, Malignant
  • AdV-tk
  • +5 more
  • Los Angeles, California
  • +7 more
Jan 30, 2023

Solid Tumor Trial (CP-506, Carboplatin, Immune checkpoint inhibitor)

Not yet recruiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • (no location specified)
Jun 23, 2022

EXploring Immune-related Adverse Events of Immune checkpoinT

Active, not recruiting
  • Cancer
  • +2 more
  • Immune checkpoint inhibitor
  • Paris, France
  • +1 more
Jul 5, 2023

Glioblastoma Trial in Atlanta, Bethesda (Nivolumab, BMS-986016)

Recruiting
  • Glioblastoma
  • Atlanta, Georgia
  • +1 more
Sep 21, 2022

NSCLC, Squamous Cell Carcinoma of the Head and Neck Trial in Lexington (Immune checkpoint inhibitor, Radiation Therapy)

Recruiting
  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Immune checkpoint inhibitor
  • Radiation Therapy
  • Lexington, Kentucky
    University of Kentucky Markey Cancer Center
Nov 10, 2022

Cutaneous Toxicity From ICI Therapy Trial in Baltimore (Immune checkpoint inhibitor (ICI))

Completed
  • Cutaneous Toxicity From ICI Therapy
  • Immune checkpoint inhibitor (ICI)
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Care Center
May 19, 2021

Immune Checkpoint Inhibitor-related Cardiotoxicity

Not yet recruiting
  • Immune Checkpoint Inhibitors, Cardiotoxicity
  • Cardiac magnetic resonance
  • (no location specified)
Nov 10, 2023

Liver Metastasis Colon Cancer Trial (IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN)

Not yet recruiting
  • Liver Metastasis Colon Cancer
  • IRE plus checkpoint inhibitor
  • IRE plus Checkpoint Inhibitor plus CpG-ODN
  • (no location specified)
Sep 13, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

Not yet recruiting
  • NSCLC Associated With Leptomeningeal Metastases
  • Tislelizumab, pemetrexed
  • (no location specified)
Nov 21, 2023

Immune Checkpoint Inhibitor Monotherapy or Combined With

Not yet recruiting
  • Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
Jan 30, 2023

Glioblastoma, Gliosarcoma, Malignant Glioma Trial run by the NCI (TMZ, ipilimumab 3mg/kg, Nivolumab)

Recruiting
  • Glioblastoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Head Neck Cancer, Lung Cancer Trial in Rouen (Vascular investigation)

Recruiting
  • Head and Neck Cancer
  • Lung Cancer
  • Vascular investigation
  • Rouen, France
  • +1 more
Dec 9, 2022

Pancreas Cancer Trial (Nivolumab, Irreversible electroporation (IRE))

Not yet recruiting
  • Pancreas Cancer
  • (no location specified)
Jun 27, 2022

Immune Related Adverse Events, Colitis, Hepatitis Trial in Freiburg (ECP)

Recruiting
  • Immune Related Adverse Events
  • +3 more
  • Freiburg, Baden-Württemberg, Germany
    Medical Center - University of Freiburg Albert-Ludwigs-Universit
Jun 9, 2022

NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • radiotherapy
  • +3 more
  • (no location specified)
Sep 10, 2023